Harrow (HROW) is partnering with a subsidiary of privately held Nordic Group for the launch of an authorized generic of Maxitrol ophthalmic suspension to treat bacterial eye infections.

Financial terms of the partnership were not disclosed.

Harrow has sold Maxitrol in the US since obtaining commercial rights to the combination of neomycin and polymyxin B sulfate and dexamethasone from Novartis (NVS) in December 2021.

Maxitrol and generic equivalents had annual sales of $20.8 million in the US, according to IQVIA data, as of January.

Harrow shares recently were trading about 1.3% higher on Thursday.

Price: 24.15, Change: +0.32, Percent Change: +1.34